Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular Carcinoma

This publication has 85 references indexed in Scilit:

• Diagnosis and Treatment of Alcohol-Associated Liver Disease
  JAMA, 2021
• MOOSE Reporting Guidelines for Meta-analyses of Observational Studies
  JAMA Surgery, 2021
• Seriously misleading results using inverse of Freeman‐Tukey double arcsine transformation in meta‐analysis of single proportions
  Research Synthesis Methods, 2019
• Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study
  Cancer, 2018
• Patient‐reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis
  Hepatology, 2016
• Influences of tobacco and alcohol use on hepatocellular carcinoma survival
  International Journal of Cancer, 2012
• Non‐alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis
  International Journal of Cancer, 2010
• Use of Surveillance for Hepatocellular Carcinoma Among Patients With Cirrhosis in the United States
  Hepatology, 2010
• Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC)
  Cancer, 2007
• Obesity and diabetes as a risk factor for hepatocellular carcinoma
  Liver Transplantation, 2004